Top Stocks
Dividend Investing
ETFs
Stock Comparison
About Us
Working with TipRanks
Follow Us
Acasti Pharma, Inc. (ACST)
NASDAQ:ACST
Acasti Pharma (ACST) Stock Price & Analysis
1,111 Followers
ACST Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.34 - $1.35
Previous Close$0.43
Volume19.62K
Average Volume (3M)124.55K
Market Cap
$19.23M
Enterprise Value-$11.52M
Total Cash (Recent Filing)$31.26M
Total Debt (Recent Filing)$503.00K
Price to Earnings (P/E)-1.1
Beta0.82
Next Earnings
Jun 28, 2023EPS Estimate
-$0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.39
Shares Outstanding44,612,831
10 Day Avg. Volume39,590
30 Day Avg. Volume124,545
Standard Deviation0.36
R-Squared0.05
Alpha-0.00084
Financial Highlights & Ratios
Price to Book (P/B)1.34
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio-1.20
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.63
Forecast
1Y Price Target
$2.50Price Target Upside479.91% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Acasti Pharma News
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Product Monthly Users
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ACST FAQ
What was Acasti Pharma, Inc.’s price range in the past 12 months?
Acasti Pharma, Inc. lowest stock price was $0.34 and its highest was $1.35 in the past 12 months.
What is Acasti Pharma, Inc.’s market cap?
Currently, no data Available
When is Acasti Pharma, Inc.’s upcoming earnings report date?
Acasti Pharma, Inc.’s upcoming earnings report date is Jun 28, 2023 which is in 91 days.
How were Acasti Pharma, Inc.’s earnings last quarter?
Acasti Pharma, Inc. released its earnings results on Feb 14, 2023. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.123 by $0.033.
Is Acasti Pharma, Inc. overvalued?
According to Wall Street analysts Acasti Pharma, Inc.’s price is currently Undervalued.
Does Acasti Pharma, Inc. pay dividends?
Acasti Pharma, Inc. does not currently pay dividends.
What is Acasti Pharma, Inc.’s EPS estimate?
Acasti Pharma, Inc.’s EPS estimate is -$0.12.
How many shares outstanding does Acasti Pharma, Inc. have?
Acasti Pharma, Inc. has 44,612,830 shares outstanding.
What happened to Acasti Pharma, Inc.’s price movement after its last earnings report?
Acasti Pharma, Inc. reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.123. Following the earnings report the stock price went up 3.125%.
Which hedge fund is a major shareholder of Acasti Pharma, Inc.?
Currently, no hedge funds are holding shares in ACST
---
Acasti Pharma Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (479.91% Upside)
$2.50 (479.91% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 4.1%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-63.16%
12-Months-Change
Fundamentals
Return on Equity
-16.60%
Trailing 12-Months
Asset Growth
2.25%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Acasti Pharma, Inc.
Acasti Pharma, Inc. engages in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. It focuses on the research of prescription drugs using omega-3, fatty acids derived from krill oil. The company was founded by Henri Harland on February 1, 2002 and is headquartered in Laval, Canada.
---
Top 5 ETFs holding ACST
Currently, no data available
Please return soon. This page is being updated.
Up to five ETFs with an Outperform Smart Score that hold ACST. The ETFs are listed according to market value of ACST within the ETF
---
---